Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Adding a Gastrointestinal Subscore to SOFA2 for Mortality Risk Assessment in the ICU: The SOFA2-GIS Study (SOFA2-GIS)

20 maggio 2026 aggiornato da: Ozkul Yilmaz Colak

Development and Validation of the SOFA2-GIS Score: Adding a Gastrointestinal Subscore to SOFA2 for Mortality Risk Assessment in Critically Ill Patients - A Multicenter Prospective Observational Cohort Study

The goal of this observational study is to learn whether adding a gastrointestinal (GI) component to a widely used organ failure score improves the prediction of death risk in critically ill adults treated in the intensive care unit (ICU).

The Sequential Organ Failure Assessment 2 (SOFA2) score is used in ICUs to measure how severely a patient's organs are failing. The current version evaluates six organ systems but does not include the gastrointestinal system, even though gut dysfunction is common and serious in critically ill patients. Researchers in this study will add a GI subscore based on the European Society of Intensive Care Medicine (ESICM) Acute Gastrointestinal Injury (AGI) classification and create a new combined score called SOFA2-GIS.

The main questions this study aims to answer are:

Does adding a gastrointestinal subscore to the SOFA2 score improve the prediction of 28-day mortality in ICU patients? Does the new SOFA2-GIS score perform better than the standard SOFA2 score in identifying patients at higher risk of dying in the ICU or in the hospital?

Researchers will compare the standard SOFA2 score with the new SOFA2-GIS score in the same patients to see which one better predicts patient outcomes.

Participants will:

Receive their usual ICU care without any change, additional treatment, or extra tests Be evaluated using routinely collected clinical and laboratory information during the first 24 hours of ICU admission Be followed during their hospital stay to record outcomes such as length of stay, need for mechanical ventilation, need for dialysis, and survival

This is a multicenter, prospective, observational cohort study conducted in tertiary ICUs in Türkiye. No additional procedures, tests, or interventions will be performed for the purpose of this study.

Panoramica dello studio

Descrizione dettagliata

Background and Rationale The Sequential Organ Failure Assessment (SOFA) score, originally introduced in 1996, has been widely used to describe and monitor organ dysfunction in critically ill patients across six organ systems: respiratory, cardiovascular, hepatic, renal, neurological, and coagulation. A revised version, SOFA2, was developed in 2024 by an international consortium under the European Society of Intensive Care Medicine (ESICM) to better reflect contemporary intensive care practice and to incorporate evidence-based threshold revisions derived from large modern ICU databases.

Despite this update, SOFA2 still does not include the gastrointestinal (GI) system. Acute gastrointestinal dysfunction is highly prevalent in critically ill patients and has been independently associated with increased mortality, prolonged ICU stay, and higher rates of nosocomial infection. The Acute Gastrointestinal Injury (AGI) classification, proposed by the ESICM Working Group on Abdominal Problems in 2012, provides a structured framework to grade GI dysfunction from Grade I (increased risk of GI dysfunction) to Grade IV (life-threatening GI failure). Despite its conceptual robustness, the AGI classification has not been formally integrated into a unified organ dysfunction score.

This study aims to address this gap by developing and prospectively evaluating SOFA2-GIS - a composite score combining the SOFA2 score with a gastrointestinal subscore derived from the AGI classification - and comparing its prognostic performance against the standard SOFA2 score in adult ICU patients. The study will be reported in accordance with the TRIPOD+AI 2024 reporting standards for prediction model studies.

Study Design and Procedures

This is a multicenter, prospective, observational cohort study conducted in tertiary adult intensive care units. Eligible patients will be evaluated at two predefined time points:

T24 (primary time point): Within the first 24 hours of ICU admission, the worst values of clinical and laboratory parameters will be used to calculate the SOFA2 score and the AGI grade. The two components will then be combined to derive the SOFA2-GIS score.

T72 (secondary time point): At the 72nd hour (±6 hours) of ICU admission, both scores will be recalculated using cross-sectional measurements, allowing the calculation of Δ-SOFA2 and Δ-SOFA2-GIS (T72 - T24).

AGI grading will follow the original ESICM 2012 criteria, based on clinical symptoms, feeding intolerance, intra-abdominal pressure, gastric residual volume, diarrhea, and gastrointestinal bleeding. To ensure consistency across centers, all participating investigators will undergo standardized training on AGI assessment. Inter-rater agreement will be evaluated through a pilot phase using shared cases prior to the main enrollment period.

No additional interventions, laboratory tests, imaging studies, or sampling procedures will be performed for the purpose of this study. All data will be derived from information collected during routine clinical care.

Data Collection

Data will be collected at the participating sites using a standardized case report form. In addition to the SOFA2 and AGI components, the following variables will be recorded:

Demographic characteristics, comorbidities (Charlson Comorbidity Index), admission category, and admission diagnosis Vital signs, laboratory parameters, mechanical ventilation parameters (including plateau and peak airway pressures), vasopressor use, and renal replacement therapy requirement Sepsis status according to the Sepsis-3 definition Lactate values at baseline, 24th hour, and 72nd hour, and the 24-hour lactate clearance 24-hour cumulative fluid balance Daily caloric intake (DCI) averaged over the first 72 hours (kcal/kg/day) Feeding intolerance, gastrointestinal bleeding, intra-abdominal hypertension, abdominal compartment syndrome, and decompressive laparotomy Acute kidney injury staged according to KDIGO criteria Clinical outcomes: ICU and hospital length of stay, ventilator-free days, vasopressor-free days, renal replacement therapy-free days, 28-day mortality, and 90-day mortality Each participating site will record anonymized patient data into a shared spreadsheet template. The data will then be transferred to and consolidated at the coordinating center, which will not have access to patient identifiers.

Statistical Approach The discriminative performance of SOFA2 and SOFA2-GIS for predicting 28-day mortality (primary outcome) will be compared using the area under the receiver operating characteristic curve (AUC-ROC), with statistical comparison performed via the DeLong test. Calibration will be assessed using the Hosmer-Lemeshow test and calibration plots. Reclassification performance will be evaluated using the net reclassification improvement (NRI) and integrated discrimination improvement (IDI) indices. Multicollinearity between score components will be assessed using the variance inflation factor (VIF).

Secondary analyses will include: comparison of Δ-SOFA2 and Δ-SOFA2-GIS (T72 - T24) for outcome prediction, subgroup analyses by admission category (medical, surgical, septic) and AGI severity grade, evaluation of the interaction between lactate clearance and AGI grade, and the development of a clinically applicable nomogram based on the best-performing model.

Study Conduct The study will be conducted in accordance with the principles of the Declaration of Helsinki. The coordinating center is the Internal Medicine Intensive Care Unit of Ondokuz Mayıs University. Participating centers will join through an open call disseminated via Turkish intensive care societies, following completion of their respective institutional approvals. Each center will obtain its own local ethics committee approval prior to enrolling patients. Reporting will follow the TRIPOD+AI 2024 guideline.

Tipo di studio

Osservativo

Iscrizione (Stimato)

800

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Adult patients (≥18 years) consecutively admitted to participating tertiary intensive care units in Türkiye. The study population includes both medical and surgical ICU admissions, with a broad mix of admission diagnoses representative of contemporary critical care practice. Patients will be enrolled regardless of underlying disease, as long as they meet eligibility criteria within the first 24 hours of ICU admission.

Descrizione

Inclusion Criteria:

  • Adults aged 18 years or older
  • Admission to a participating intensive care unit
  • Expected ICU length of stay of at least 24 hours
  • Availability of clinical and laboratory data required to calculate the SOFA2 score and the AGI grade within the first 24 hours of ICU admission
  • Written informed consent obtained from the patient or, when not feasible due to the patient's clinical condition, from a legally authorized representative

Exclusion Criteria:

  • Age younger than 18 years
  • Pregnancy
  • ICU length of stay shorter than 24 hours (including patients who die or are discharged within the first 24 hours)
  • ICU readmission during the same hospital stay (only the index admission will be included)
  • Postoperative admission for routine monitoring without organ dysfunction (planned short-term observation following elective surgery)
  • Admission solely for end-of-life care or with treatment limitations (do-not-resuscitate or withdrawal of life-sustaining therapy decisions) made within the first 24 hours of admission
  • Patients with primary gastrointestinal pathology as the reason for ICU admission that would confound AGI grading (e.g., gastrointestinal surgery within the preceding 7 days, acute mesenteric ischemia as the primary diagnosis)
  • Patients with anatomical or functional conditions precluding standard AGI assessment (e.g., short bowel syndrome, permanent gastrostomy/jejunostomy with chronic feeding intolerance, chronic intestinal pseudo-obstruction)
  • Refusal of consent by the patient or legal representative
  • Participation in an interventional clinical trial that may affect outcome measures

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Comparison of discriminative performance between SOFA2 and SOFA2-GIS scores for 28-day all-cause mortality
Lasso di tempo: 28 days from ICU admission

The primary outcome is the difference in the area under the receiver operating characteristic curve (ΔAUC) between the SOFA2-GIS score and the SOFA2 score for predicting 28-day all-cause mortality.

Both scores are calculated within the first 24 hours of ICU admission using the worst recorded values of each component. The Sequential Organ Failure Assessment 2 (SOFA2) score evaluates six organ systems (respiratory, cardiovascular, hepatic, renal, neurological, and coagulation), each scored from 0 to 4, with a total range of 0 to 24; higher scores indicate worse organ dysfunction. The SOFA2-GIS score combines SOFA2 with a gastrointestinal subscore (Grade 0-IV, scored 0-4) derived from the ESICM 2012 Acute Gastrointestinal Injury classification, with a total range of 0 to 28; higher scores indicate worse organ dysfunction.

The area under the receiver operating characteristic curve (AUC-ROC) ranges from 0.5 (no discrimination) to 1.0 (perfect discrimination); higher values indicate better

28 days from ICU admission

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Difference in discriminative performance (ΔAUC) between SOFA2-GIS and SOFA2 for prediction of 90-day all-cause mortality
Lasso di tempo: 90 days from ICU admission
The difference in the area under the receiver operating characteristic curve (ΔAUC) between SOFA2-GIS and SOFA2 scores (calculated within the first 24 hours of ICU admission) will be evaluated for predicting 90-day all-cause mortality. ΔAUC = AUC(SOFA2-GIS) - AUC(SOFA2). AUC-ROC ranges from 0.5 to 1.0; ΔAUC ranges from -0.5 to +0.5, with positive values indicating better performance of SOFA2-GIS. Statistical comparison via the DeLong test.
90 days from ICU admission
Difference in discriminative performance (ΔAUC) between SOFA2-GIS and SOFA2 for prediction of ICU mortality
Lasso di tempo: Through ICU discharge, up to 60 days from ICU admission
The difference in AUC-ROC between SOFA2-GIS and SOFA2 scores will be evaluated for predicting all-cause ICU mortality. ΔAUC = AUC(SOFA2-GIS) - AUC(SOFA2), ranges from -0.5 to +0.5; positive values indicate better performance of SOFA2-GIS. Statistical comparison via the DeLong test.
Through ICU discharge, up to 60 days from ICU admission
Difference in discriminative performance (ΔAUC) between Δ-SOFA2-GIS and Δ-SOFA2 for prediction of 28-day all-cause mortality
Lasso di tempo: From ICU admission to 28 days
Δ-SOFA2 and Δ-SOFA2-GIS will be calculated as the change in scores between the 72nd hour and 24th hour of ICU admission (T72 - T24). Δ-SOFA2 ranges from -24 to +24, and Δ-SOFA2-GIS ranges from -28 to +28; positive values indicate clinical deterioration, negative values indicate improvement. The difference in AUC-ROC between Δ-SOFA2-GIS and Δ-SOFA2 for predicting 28-day all-cause mortality will be calculated as ΔAUC = AUC(Δ-SOFA2-GIS) - AUC(Δ-SOFA2), with statistical comparison via the DeLong test.
From ICU admission to 28 days
Net Reclassification Improvement (NRI) of SOFA2-GIS over SOFA2 for 28-day all-cause mortality
Lasso di tempo: 28 days from ICU admission
Net Reclassification Improvement (NRI) quantifies the proportion of patients reclassified into more accurate risk categories when SOFA2-GIS is used instead of SOFA2 for predicting 28-day all-cause mortality. NRI ranges from -2 to +2; positive values indicate that SOFA2-GIS improves risk classification compared with SOFA2.
28 days from ICU admission
Intensive care unit length of stay
Lasso di tempo: Up to 60 days from ICU admission
Time from ICU admission to ICU discharge alive, ICU death, or transfer to another ICU, measured in days. Patients still in ICU at day 60 will be right-censored at day 60. Association of SOFA2 and SOFA2-GIS scores with ICU length of stay will be assessed using time-to-event analysis (Cox proportional hazards regression, treating death as a competing risk).
Up to 60 days from ICU admission

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Ozkul Yilmaz Colak, MD, Ondokuz Mayıs University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 luglio 2026

Completamento primario (Stimato)

1 dicembre 2026

Completamento dello studio (Stimato)

1 marzo 2027

Date di iscrizione allo studio

Primo inviato

8 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

8 maggio 2026

Primo Inserito (Effettivo)

14 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

26 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

20 maggio 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

Descrizione del piano IPD

De-identified individual participant data (IPD) collected during the SOFA2-GIS study, including all variables underlying the published findings, will be made available. The dataset will include patient demographics, comorbidities, admission diagnosis, SOFA2 and AGI score components, laboratory parameters, hemodynamic and ventilatory parameters, lactate values, daily caloric intake, fluid balance, complications, and clinical outcomes (28-day, ICU, hospital, and 90-day mortality, length of stay, ventilator-free days, vasopressor-free days, RRT-free days). All direct patient identifiers will be removed prior to data sharing.

Periodo di condivisione IPD

Data will be available beginning 6 months and ending 5 years following publication of the primary results manuscript.

Criteri di accesso alla condivisione IPD

Access will be granted to researchers who provide a methodologically sound proposal, approved by the steering committee of the SOFA2-GIS study group. Proposals should be directed to the principal investigator (Dr. Mustafa Bilgiç, Ondokuz Mayıs University) and should include a statistical analysis plan and a clear scientific question. To gain access, requesters will need to sign a data access agreement, including a commitment not to attempt to re-identify participants.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF
  • CODICE_ANALITICO
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

3
Sottoscrivi